Erratum: Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: The phase III lefamulin evaluation against pneumonia (LEAP 1) trial (Clinical Infectious Diseases DOI: 10.1093/cid/ciz090);Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation against Pneumonia (LEAP 1) Trial

Clinical Infectious Diseases

Volumn 69, Issue 11, 2019, Pages 1856-1867

  File, Thomas M ^a   Goldberg, Lisa ^b   Das, Anita ^c   Sweeney, Carolyn ^b   Saviski, John ^b   Gelone, Steven P ^b   Seltzer, Elyse ^d   Paukner, Susanne ^b   Wicha, Wolfgang W ^b   Talbot, George H ^e   Gasink, Leanne B ^b  

^a Infectious Disease Section   (United States)

^b Nabriva Therapeutics Inc   (Austria)

^c Das Consulting   (United States)

^d UroGen Pharma Ltd   (United States)

^e Talbot Advisors LLC   (United States)

Author keywords

antibiotic; lefamulin; moxifloxacin; pleuromutilin; pneumonia

Indexed keywords

ALANINE AMINOTRANSFERASE; LEFAMULIN; LINEZOLID; MOXIFLOXACIN; ANTIINFECTIVE AGENT; DITERPENOID; PLEUROMUTILIN; POLYCYCLIC HYDROCARBON; THIOGLYCOLIC ACID DERIVATIVE;

ACINETOBACTER INFECTION; ACINETOBACTER JUNII; ACINETOBACTER LWOFFII; ACUTE RESPIRATORY FAILURE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; ARTICLE; ATRIAL FIBRILLATION; BACTERIAL PNEUMONIA; BACTERIUM ISOLATE; BRADYCARDIA; BURKHOLDERIA CEPACIA INFECTION; CEREBROVASCULAR ACCIDENT; CHLAMYDIAL PNEUMONIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CITROBACTER KOSERI; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMPARATIVE STUDY; CONFUSION; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYSTITIS; DEATH; DIARRHEA; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; ERYTHEMA; ESCHERICHIA COLI PNEUMONIA; EUROPEAN MEDICINES AGENCY; FEMALE; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GROUP A STREPTOCOCCAL INFECTION; HAEMOPHILUS INFECTION; HAEMOPHILUS PARAINFLUENZAE; HEART ARREST; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEMATEMESIS; HEMORRHAGIC SHOCK; HUMAN; HYPERTENSION; HYPOKALEMIA; INFUSION RELATED REACTION; INJECTION SITE REACTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; KLEBSIELLA PNEUMONIAE INFECTION; LEGIONNAIRE DISEASE; LIVER FUNCTION TEST; LUNG EMBOLISM; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORAXELLACEAE INFECTION; MULTICENTER STUDY; MYCOPLASMA PNEUMONIA; NAUSEA; PAIN; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PLEURA EFFUSION; PLEURA EMPYEMA; PNEUMONIA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SEMINOMA; SEPSIS; SERRATIA INFECTION; SIDE EFFECT; STAPHYLOCOCCUS AUREUS INFECTION; STREPTOCOCCUS PNEUMONIA; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; ANTI-BACTERIAL AGENTS; DITERPENES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LINEZOLID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOXIFLOXACIN; PNEUMONIA, BACTERIAL; POLYCYCLIC COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOGLYCOLATES;

EID: 85071186281     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciz775     Document Type: Erratum

References (30)

1. Jain S, Self WH, Wunderink RG, et al; CDC EPIC Study Team. Communityacquired pneumonia requiring hospitalization among U. S. adults. N Engl J Med 2015; 373:415-27.
2. Sherwin RL, Gray S, Alexander R, et al. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged 50 years with community-acquired pneumonia. J Infect Dis 2013; 208:1813-20.
3. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 2012; 67:71-9.
4. Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia. Clin Infect Dis 2016; 62:817-23.
5. Cunha BA. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed? Chest 2004; 125:1913-9.
6. Mandell LA, Wunderink RG, Anzueto A, et al; Infectious Diseases Society of America; American Thoracic Society. Infectious Diseases Society of America/ American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
7. Arnold FW, Summersgill JT, Lajoie AS, et al; Community-Acquired Pneumonia Organization (CAPO) Investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med 2007; 175:1086-93.
8. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: https://www. cdc. gov/drugresistance/threat-report-2013/index. html. Accessed 23 March 2018.
9. Cherazard R, Epstein M, Doan TL, Salim T, Bharti S, Smith MA. Antimicrobial resistant Streptococcus pneumoniae: prevalence, mechanisms, and clinical implications. Am J Ther 2017; 24:e361-9.
10. Pereyre S, Goret J, Bebear C. Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment. Front Microbiol 2016; 7:1-11.
11. US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Available at: https://www. fda. gov/Drugs/DrugSafety/ ucm511530. htm. Accessed 23 March 2018.
12. US Food and Drug Administration. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Available at: https://www. fda. gov/downloads/ Drugs/DrugSafety/UCM612834. pdf. Accessed 18 July 2018.
13. Eyal Z, Matzov D, Krupkin M, et al. A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism. Sci Rep 2016; 6:1-8.
14. Paukner S, Sader HS, Ivezic-Schoenfeld Z, Jones RN. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother 2013; 57: 4489-95.
15. Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012; 56:1619-23.
16. Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother 2012; 67:1170-5.
17. Waites KB, Crabb DM, Duffy LB, Jensen JS, Liu Y, Paukner S. In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China. Antimicrob Agents Chemother 2017; 61:e02008-e02016.
18. Mendes RE, Farrell DJ, Flamm RK, et al. In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States. Antimicrob Agents Chemother 2016; 60:4407-11.
19. Jacobsson S, Paukner S, Golparian D, Jensen JS, Unemo M. In vitro activity of the novel pleuromutilin lefamulin (BC-3781) and effect of efflux pump inactivation on multidrug-resistant and extensively-drug resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother 2017; 61:e01497-01417.
20. Zeitlinger M, Schwameis R, Burian A, et al. Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid. J Antimicrob Chemother 2016; 71:1022-6.
21. Wicha WW, Lell C, Seltzer E, Prince WT, Gelone SP. Pharmacokinetics and safety of an oral, immediate-release (IR) tablet formulation of lefamulin in fed and fasted healthy subjects. Poster presented at: 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, 22-25 April 2017.
22. US Food and Drug Administration. Guidance for industry. community-acquired bacterial pneumonia: developing drugs for treatment. US Department of Health and Human Services. Available at: https://www. fda. gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM123686. pdf. Accessed 27 November 2018.
23. AVELOX (moxifloxacin). Full prescribing information. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc, 2013.
24. Foundation for the National Institutes of Health Biomarkers Consortium Project Team. Recommendations to the FDA for interim endpoints for clinical trials in community-acquired bacterial pneumonia. CABP Docket ID: FDA-2009-D-0136. North Bethesda, MD: Foundation for the National Institutes of Health, 2011.
25. Committee for Human Medicinal Products. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. London, United Kingdom: European Medicines Agency, 2013.
26. US Food and Drug Administration. Guidance for industry drug-induced liver injury: premarketing clinical evaluation. US Department of Health and Human Services. Available at: https://www. fda. gov/downloads/guidances/UCM174090. pdf. Accessed 27 November 2018.
27. Del Valle-Mendoza J, Silva-Caso W, Cornejo-Tapia A, et al. Molecular etiological profile of atypical bacterial pathogens, viruses and coinfections among infants and children with community acquired pneumonia admitted to a national hospital in Lima, Peru. BMC Res Notes 2017; 10:1-6.
28. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010; 51:1395-405.
29. File TM, Rewerska B, Vucinic-Mihailovic V, et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis 2016; 63:1007-16.
30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41.